Dr. El. Georgakopoulos
Dr. Georgakopoulos is one of the world’s leading scientists in the field of genetics and molecular biology, with a huge scientific and research work and numerous awards.
He was specialized in genetics by the eminent University of Heidelberg Professor K.-H. Matzura and in Neurophysiology by the distinguished Professor of the School of Medicine of the same University, M. Zimmerman.
He is a Member of the New York Academy of Sciences, while he has collaborated in research and science with Nobel laureates in the fields of medicine and biology. He collaborated for 3 years with Carlos Cordon Cardo, who was nominated for the Nobel Prize for the discovery of the breast cancer gene, HER2.
Dr. Georgakopoulos has been active, among others, in the fields of biotechnology, molecular diagnostics, nanobiotechnology and molecular applications. He holds 17 national and international patents and has been awarded with numerous national and international awards.
During his scientific career, he founded and organized the Molecular Biology and Genetics Unit at the Athens Medical Center, where he developed special activity with the execution of 5 research programs, in epithelial type cancer and the possibility of early diagnosis of micrometastatic disease in cancers of epithelial organs.
He directed Acrogenomics Inc, listed on the New York Stock Exchange, one of the largest companies in the world in genetics and nanotechnology. The company’s research program aimed at developing nanoparticles and identifying their properties for use in clinical applications.
In 2008 he took over the management of the stem cell quality system of the Hygeia group.
Publications
1. Georgakopoulos E., McMenamin M. and Skouteris GG (1995): “Phospholipase A2 is activated by tumor necrosis factor -α in primary hepatocytes stimulated by a deleted form of hepatocyte growth factor”. Biochemical and Biophysical Research Communication, 217, 1263-1270.
2. Skouteris GG and Georgakopoulos E. (1996): “Hepatocyte growth factor induced proliferation of primary hepatocytes is mediated by activation of phosphatidylinositol 3-kinase”. Biochemical and Biophysical Research Communication, 218, 229-233.
3. Blume A., Georgakopoulos E., Lebrun C., Culman J., Möllenhoff E., Herdegen T. and Unger T. (1996): “Arginine-vasopressin as target of angiotensin II in the brain in vitro”. Regulatory Peptides, Volume 64, 1-3, 14.
4. Herdegen T., Blume A., Buschman T., Georgakopoulos E., Winier C., Schmid W., Hsiem F., Zimmerman M and Gass P. (1997): “Expression of activating transcription factor-2, serum response factor and cAMP/Ca response element binding protein in the adult rat brain following generalized seizures, nerve fiber lesion and ultraviolet irradiation”. Neuroscience, 81, 190-212.
5. Karanikiotes C., Skiadas I., Karina M., Georgakopoulou S., Georgakopoulos E. and Fountzilas G (2005): “Novel chromatographic molecular method for the detection of the membrane cancer antigen Ep-CAM (17-1A) in peripheral blood and bone marrow of patients with metastatic colorectal cancer”, Anticancer Research, Jan-Feb; 25(1A): 319-23.
6. Papadopoulou E., DavilasE., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos K, Aggelakis F., Dardoufas K., Agnanti JN., Karydas I, Nasioulas G. (2006): “Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer”, Annals of the New York Academy of Sciences, 1075, 2423-2435.
